Q4 Earnings Estimate for ATXS Issued By Lifesci Capital

Key Points

• Astria Therapeutics is projected to report earnings of ($0.52) per share for Q4 2025, with a current full-year estimate of ($1.65) per share as indicated by Lifesci Capital analysts.
• The company's stock recently traded at $6.96 and has a market capitalization of $392.98 million, reflecting significant institutional investment with 98.98% of shares owned by institutional investors.
• Astria Therapeutics has received favorable ratings from several research firms, with a consensus rating of "Buy" and a price target of $29.00.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Stock analysts at Lifesci Capital issued their Q4 2025 earnings per share estimates for shares of Astria Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Lifesci Capital analyst S. Slutsky expects that the biotechnology company will post earnings of ($0.52) per share for the quarter. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.04.

Several other research firms have also recently issued reports on ATXS. Cantor Fitzgerald reiterated an "overweight" rating and issued a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Wednesday. JMP Securities upped their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a report on Wednesday. Finally, Citigroup reiterated an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Astria Therapeutics has a consensus rating of "Buy" and a consensus price target of $29.00.

Astria Therapeutics Trading Up 1.4%

Astria Therapeutics stock traded up $0.09 during mid-day trading on Thursday, hitting $6.96. The stock had a trading volume of 15,968 shares, compared to its average volume of 358,286. The stock has a 50-day simple moving average of $6.19 and a two-hundred day simple moving average of $5.77. The stock has a market capitalization of $392.98 million, a PE ratio of -3.38 and a beta of 0.48. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its holdings in shares of Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,557 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after buying an additional 7,971 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Astria Therapeutics by 1,079.6% during the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company's stock worth $46,000 after buying an additional 7,957 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after buying an additional 2,766 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Astria Therapeutics during the fourth quarter worth about $50,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.